A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort

Hepatocellular carcinoma (HCC) staging guides patient prognosis and treatment allocation; however, there is no universally accepted staging system for HCC. The most widely endorsed staging system is the Barcelona Clinic Liver Cancer (BCLC) system, which incorporates tumor burden, functional status, and liver function.1 We aimed to compare the discriminant ability of several staging systems for HCC in a geographically diverse multicenter United States (US) cohort.